Authors

Latest:

Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.

Evan T. Hall, MD, MPhil

Evan Hall, MD MPhil, is a medical oncologist who specializes in the treatment of skin cancers (including melanoma) and kidney cancer.

Latest:

Dr Hall on Unmet Needs in Later-Line RCC

Evan T. Hall, MD, Mphil, discusses several avenues for future research in later-line renal cell carcinoma.

Alex Duval, MD, PhD

Latest:

Dr. Duval on the Use of MSI-H as a Biomarker of Response in Patients With Cancer

Alex Duval, MD, PhD, discusses the use of microsatellite instability–high as a biomarker of response to therapy in patients with cancer.

Gerhardt Attard, MD, PhD, FRCP

Gerhardt Attard

Latest:

Dr Attard on Niraparib/Abiraterone Acetate Plus Prednisone in mCRPC With HRR Alterations

Gerhardt Attard, MD, PhD, FRCP, discusses niraparib plus abiraterone acetate and prednisone in mCSPC with HRR gene alterations.

Cortney Eakin, MD

Latest:

Dr. Eakin on Racial Disparities in Uterine Cancer

Cortney Eakin, MD, discusses racial disparities and histology trends in uterine cancer.

Sasha Stanton, MD

Latest:

Dr. Stanton on Improving Responses to Immunotherapy in Early-Stage HR+ Breast Cancer

Sasha Stanton, MD, discusses efforts to improve the responses to immunotherapy regimens in early-stage hormone receptor–positive breast cancer.

Morgan Bayer

Latest:

Real-World Data Show Enfortumab Vedotin Significantly Improves OS in Urothelial Carcinoma

Enfortumab vedotin significantly improved outcomes for patients with unresectable or metastatic urothelial carcinoma, according to real-world data.

Christopher Morse, MD

Latest:

Taking Action to Individualize Ovarian Cancer Care: Key Takeaways

In this fifth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, share key takeaways from their discussion on how to best individualize care for patients with ovarian cancer.

April Rose, MD

Latest:

Dr. Rose on the Results of the BEAVER Trial in Non-V600E BRAF-Mutant Advanced Solid Tumors

April Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.

Joshua Strauss, MD

Latest:

Dr. Strauss on Future Research Directions in SCLC

Joshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.

Sanjeet Singh Dadwal, MD

Latest:

Dr. Dadwal on the Investigation of Posoleucel Following Allogeneic HCT

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

Lindsay Fischer

Latest:

Fostering Interactions That Heal

The pain and suffering that Eduardo Bruera, MD, FAAHPM, witnessed in patients during his clinical oncology rotations motivated him to reshape palliative care treatment.

Bradley Monk, MD, FACS, FACOG

Latest:

Dr Monk on the Investigation of B7-H4–Directed Vedotin ADCs in Gynecologic Cancers

Bradley Monk, MD, FACS, FACOG, discusses the rationale for investigating B7-H4–directed vedotin antibody-drug conjugates and highlights how these agents may address unmet needs for patients with gynecologic cancers.

Anirudh Rai, MD

Latest:

Empowering Community Cancer Care: Importance of Collaboration

In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.

Guillermo Garcia-Manero, MD

Guillermo Garcia-Manero, MD, is director of the Fellowship Program, the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, deputy chair of Translational Research, a professor, and chief of the Section of Myelodysplastic Syndromes in the Department of Leukemia, as well as leader of the MDS/AML Moon Shot Program at The University of Texas MD Anderson Cancer Center in Houston.

Latest:

Dr Garcia-Manero on Dual IRAK4/FLT3 Inhibition With Emavusertib in MDS and AML

Guillermo Garcia-Manero, MD, discusses the rationale for investigating the dual inhibition of IRAK4 and FLT3 with emavusertib in MDS and AML

Alexander Putnam Cole, MD

Latest:

Dr Cole on the Rationale for Investigating Race-based Disparities in Prostate Cancer–Specific Survival

Alexander Putnam Cole, MD, discusses the rationale for investigating the magnitude of racial and ethnic disparities in prostate cancer–specific survival in patients undergoing surgery vs radiotherapy.

James Catto, MB, ChB, PhD, FRCS

Latest:

Dr Catto on the Utility of Erdafitinib in High-Risk nMIBC With FGFR Alterations

James Catto, MB, ChB, PhD, FRCS, discusses the utility of erdafitinib in patients with high-risk non–muscle-invasive bladder cancer with select FGFR alterations who have received prior treatment with Bacillus Calmette–Guérin.

Zaraq Khan, MBBS

Latest:

Dr. Khan on the Ideal Patients for GnRH Agonists in Breast Cancer

Zaraq Khan, MBBS, discusses which patients with breast cancer would be ideal candidates to receive treatment with a GnRH agonist for ovarian protection.

Nicolaus Kröger, MD

Latest:

Dr. Kröger on Toxicities Associated With Allogeneic Stem Cell Transplant in Myeloma

Nicolaus Kröger, MD, discusses toxicities associated with allogeneic stem cell transplant in patients with multiple myeloma.

Neil M. Iyengar, MD

Latest:

Exciting New Data for TNBC Therapies

Panelists discuss how new trial results from ASCENT-03 and TROPION-Breast02 are shaping next-generation TNBC therapies.